雷贝拉唑和泮托拉唑对氯吡格雷抗血小板作用的影响

目的 探讨冠心病病人使用雷贝拉唑或泮托拉唑对氯吡格雷的抗血小板作用的影响.方法 148例冠心病病人在给予阿司匹林和氯吡格雷基础上,分成雷贝拉唑组(雷贝拉唑10 mg·d-1,n=50)、泮托拉唑组(泮托拉唑40 mg·d-1,n=48)和对照组(n=50).比较3 d后血小板聚集率.结果 三组平均血小板最大聚集率分别为雷贝拉唑组(44.4±21.1)、泮托拉唑组(39.4±21.4)、对照组(45.3±15.2),P=0.274,三组之间差异无统计学意义,三组间的氯吡格雷抵抗发生率分别为雷贝拉唑组(46.0%)、泮托拉唑组(41.7%)、对照组(38.0%),P=0.719,差异无统计学意义.结论 雷贝拉唑和泮托拉唑对氯吡格雷的抗血小板活性短期内无明显影响.

Impact of rabeprazole and pantoprazole on antiplatelet activityof clopidogrel

Objective To investigate the influence of rabeprazole and pantoprazole on antiplatelet activity of clopidogrel in patients with coronary atherosclerotic heart disease.Methods 148 patients with coronary atherosclerotic heart disease treated with aspirin and clopidogrel were randomly divided into rabeprazole group,pantoprazole group and control group.Adenosine diphosphate-induced platelet aggregation was measured to evaluate the antiplatelet effect of clopidogrel after 5 days in three groups.Results Adenosine diphosphate-induced platelet aggregation was similar among three groups:rabeprazole group(44.4±21.1),pantoprazole group(39.4±21.4)and control group(45.3±15.2),P=0.274.There was no significant difference between these groups.The incidence of clopidogrel resistance in three groups:rabeprazole group(46.0%),pantoprazole group(41.7%)and control group(38.0%),P=0.719,there was no significant difference.Conclusion There are no significant impact of rabeprazole or pantoprazole on antiplatelet activity of clopidogrel.